

|                               |                                   |                     |  |
|-------------------------------|-----------------------------------|---------------------|--|
| <b>Notice of Allowability</b> | <b>Application No.</b>            | <b>Applicant(s)</b> |  |
|                               | 10/560,013                        | BOGGS ET AL.        |  |
|                               | Examiner<br>Jason M. Nolan, Ph.D. | Art Unit<br>1626    |  |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to 08/29/2007.
2.  The allowed claim(s) is/are 1-26, 28, 38 and 39 (now renumbered 1-29).
3.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a)  All
  - b)  Some\*
  - c)  None
 of the:
  1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
  - (a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.
  - (b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

#### Attachment(s)

1.  Notice of References Cited (PTO-892)
2.  Notice of Draftsperson's Patent Drawing Review (PTO-948)
3.  Information Disclosure Statements (PTO/SB/08),  
Paper No./Mail Date 08/29/2007
4.  Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5.  Notice of Informal Patent Application
6.  Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_.
7.  Examiner's Amendment/Comment
8.  Examiner's Statement of Reasons for Allowance
9.  Other \_\_\_\_\_.

### **DETAILED ACTION**

**Claims 1-26, 28, & 38-40** are pending in the instant application; of which, **Claims 1, 15, 25, 26, 38, & 39** are currently amended. **Claims 27 & 29-37** are canceled.

#### ***Response to Amendment***

Applicant's amendments, see Amendment – After Non-Final Rejection, filed 08/29/2007, with respect to **Claims 1, 15, 25, 26, 38, & 39** have been fully considered and are entered. The 112-indefinite rejection of **Claim 26** has been withdrawn per amendment. The 112- enablement rejection of **Claims 1 & 26** has been withdrawn per amendment. The 112-enablement rejection of **Claims 38-40** has been withdrawn per Applicant's amendment and Examiner's amendment herein. The claim objections to **Claims 2-25 & 28** are withdrawn per amendment.

#### ***Information Disclosure Statement***

Applicants' information disclosure statement (IDS), filed on 08/29/2007 has been considered. Please refer to Applicants' copy of the 1449 submitted herein.

#### ***Examiner's Amendment***

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Karen Prus on October 31, 2007.

The application has been amended as follows:

1. In **Claim 38**, **after** "A method for the treatment of a papovavirus infection" and **before** "polyoma virus infection and papilloma virus infection..." **delete** ", including" and **insert** -- selected from the group consisting of --.
2. In **Claim 39**, **after** "A method for the treatment of conditions or disorders due to HPV infection" and **before** "comprising administering..." **insert** -- selected from the group consisting of genital warts and cervical dysplasia --.
3. **Delete/Cancel Claim 40.** This claim is canceled without prejudice; therefore Applicants retain the right to file divisional or continuation applications on the contents thereof.

#### ***Statement of Reasons for Allowance***

One skilled in the art would be enabled to make and use the compounds taught herein for the purpose of HPV-related disorders selected from the group consisting of genital warts and cervical dysplasia using the teachings of the Specification (assays on pages 55-56) in conjunction with the teachings in the prior art. Recent reviews by Bernard, H. (*J. of Antimicrobial Chemotherapy* **2004**, *53*, 137-139) and Eash *et al.* (*Cell.*

*Mol. Life. Sci.* **2006**, *63*, 865-876) establish that small molecule therapeutics may be used as an alternative to other treatments such as cryotherapy, laser, and hysterectomy surgeries, for example.

### **Conclusion**


**Claims 1-26, 28, 38, & 39** are allowed and are now renumbered as **Claims 1-29**.

### **Telephone Inquiry**


Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jason M. Nolan, Ph.D.** whose telephone number is **(571) 272-4356** and electronic mail is **[Jason.Nolan@uspto.gov](mailto:Jason.Nolan@uspto.gov)**. The examiner can normally be reached on Mon - Fri (9:00 - 5:30PM). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Joseph M<sup>c</sup>Kane** can be reached on **(571) 272-0699**. The fax phone number for the organization where this application or proceeding is assigned is **571-273-8300**. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Jason M. Nolan, Ph.D.  
Examiner  
Art Unit 1626



REBECCA ANDERSON  
PRIMARY EXAMINER



Joseph K. M<sup>c</sup>Kane  
Supervisory Patent Examiner  
Art Unit 1626  
Date: November 1, 2007